Related Experiment Video
Updated: Aug 13, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor
Katharina Kriegsmann1, Mark Kriegsmann2, Mathias Witzens-Harig3
1Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany. katharina.kriegsmann@med.uni-heidelberg.de.
Abstract:
The Bruton's tyrosine kinase (BTK) is an essential in the B-cell receptor (BCR) signaling pathway which was identified as crucial in the pathogenesis of B-cell malignancies. Ibrutinib, a first-in-class BTK inhibitor, has been approved for the treatment of distinct B-cell malignancies. To overcome off-target side effects of and emerging resistances to ibrutinib, more selective second-generation BTK inhibitors were developed. Acalabrutinib is a novel second-generation BTK inhibitor and has shown promising safety and efficacy profiles in phase 1/2 clinical trials in patients with relapsed CLL and pretreated MCL. Recently, acalabrutinib was approved by the FDA for treatment of adult patients with MCL who received at least one prior therapy. However, clinical trials on a direct comparison between ibrutinib and acalabrutinib and on combination treatment options with other agents as CD20 antibodies are warranted.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Receptor Tyrosine Kinases
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Treatment Resistent Cancers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

